Abstract:Abstract Background: Combined oral contraceptives (COCs) often contain ethinylestradiol (EE), an estrogen known to be associated with several side effects including venous thromboembolism. Estetrol (E4) is a native estrogen synthesized by the human fetal liver during pregnancy. Results from a phase 2 dose-finding study showed that E4 15 mg in combination with drospirenone 3 mg (E4/DRSP) resulted in a good bleeding profile and cycle control. Here, we present phase 2 results showing the effect of E4/DRSP on ovarian function. Study Design: A single-center, randomized, open-label, parallel study was conducted in healthy young volunteers with proven ovulatory cycles. Study subjects received either E4 15 mg/DRSP 3 mg (n=41) or EE 20 μg/DRSP 3 mg (n=41) in a 24/4-day regimen for three consecutive cycles. Both in cycle 1 and 3, serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH), estradiol and progesterone levels were determined, and follicular size and endometrial thickness were measured every three days using transvaginal ultrasound. Ovarian function was assessed using the Hoogland score, which considers follicular size and estradiol/progesterone levels. Return of ovulation was determined after treatment cessation. Safety and tolerability were assessed by monitoring adverse events (AEs), vital signs, physical and gynecological examination, clinical laboratory parameters, 12-lead electrocardiogram and echocardiogram. Results: No ovulations were reported during the use of E4/DRSP, while three ovulations occurred in two subjects in the EE/DRSP group. In both groups, most participants had no ovarian activity according to the Hoogland score. In cycle 1, Hoogland scores and follicular diameters were similar in both groups. In cycle 3, these parameters were slightly less suppressed in the E4/DRSP group when compared to EE/DRSP. While mean FSH and LH concentrations were less inhibited by E4/DRSP, mean estradiol and progesterone concentrations and endometrial thickness were similarly suppressed in both groups. Return of ovulation occurred on average 15.5 days after discontinuation of E4/DRSP intake. The number of frequently reported AEs considered to be related to study medication was similar for both treatment groups except for breast pain (11 subjects in the E4/DRSP group versus 4 subjects with EE/DRSP). Most related AEs were of mild or moderate intensity. Three subjects discontinued due to an AE, one with E4/DRSP (severe stress, emotional lability), and two with EE/DRSP (emotional lability, depressed mood). Other safety assessments did not show significant abnormalities. No serious AEs were reported. Conclusions: The combination of E4 15 mg and DRSP 3 mg results in adequate ovulation inhibition and ovarian function suppression, which is similar to a well-established COC containing EE/DRSP. E4/DRSP is considered safe and well-tolerated.

Oestrogens in oral contraception: considerations for tailoring prescription to women's needs

Regulatory T Cell Proportion and Phenotype Are Altered in Women Using Oral Contraception

Estradiol in non-oral hormonal contraception: a “long and winding road”

Combined oral contraceptives: health benefits beyond contraception

Combined estrogen-progestin oral contraceptives and female sexuality: an updated review

A bitter pill to swallow: adjustments to oral contraceptive pill use in polycystic ovary syndrome

Evolution of extended use of the combined oral contraceptive pill

Systematic analysis of combined oral contraceptive prescription patterns in psychotropic drug users across twelve European countries

Oral contraceptives: significance of their effects in man and relationship to findings in animal models

Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications

Safety implications of transferring the oral contraceptive from prescription-only to over-the-counter status

Insights into Vitamin E with Combined Oral Contraceptive on INSR Gene in PCOS by Integrating In Silico and In Vivo Approaches

The role of combined oral contraceptives containing norgestimate for acne vulgaris treatment: a review

Combined oral contraceptives: risks and benefits

Oral contraceptives in the treatment of acne

Pharmacokinetic Drug Interactions Involving 17 Alpha-Ethinylestradiol - A New Look At An Old Drug

Optimising delivery systems for HRT

EFS/ESSM-Certified Psychosexologist with Mark of Excellence.

[Oral Contraceptive and Risk of Disease].

The Effect of Estetrol/Drospirenone on Ovarian Function Is Similar to a Well-Established Combined Oral Contraceptive: Results From a Phase 2 Study

Pharmacokinetic Drug Interactions Involving 17Α-Ethinylestradiol